FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2910094802> ?p ?o ?g. }

• W2910094802 endingPage "2227" @default.
• W2910094802 startingPage "2219" @default.
• W2910094802 abstract "Abstract Purpose: Chemotherapy has long been the standard treatment for advanced stage non–small cell lung cancer (NSCLC), but checkpoint inhibitors are now approved for use in several patient groups and combinations. To design optimal combination strategies, a better understanding of the immune-modulatory capacities of conventional treatments is needed. Therefore, we investigated the immune-modulatory effects of paclitaxel/carboplatin/bevacizumab (PCB), focusing on the immune populations associated with the response to checkpoint inhibitors in peripheral blood. Experimental Design: A total of 223 patients with stage IV NSCLC, enrolled in the NVALT12 study, received PCB, with or without nitroglycerin patch. Peripheral blood was collected at baseline and after the first and second treatment cycle, proportions of T cells, B cells, and monocytes were determined by flow cytometry. Furthermore, several subsets of T cells and the expression of Ki67 and coinhibitory receptors on these subsets were determined. Results: Although proliferation of CD4 T cells remained stable following treatment, proliferation of peripheral blood CD8 T cells was significantly increased, particularly in the effector memory and CD45RA+ effector subsets. The proliferating CD8 T cells more highly expressed programmed death receptor (PD)-1 and cytotoxic T-lymphocyte–associated antigen-4 (CTLA-4) compared with nonproliferating CD8 T cells. Immunologic responders (iR; &gt;2 fold increased proliferation after treatment) did not show an improved progression-free (PFS) or overall survival (OS). Conclusions: Paclitaxel/carboplatin/bevacizumab induces proliferation of CD8 T cells, consisting of effector cells expressing coinhibitory checkpoint molecules. Induction of proliferation was not correlated to clinical outcome in the current clinical setting. Our findings provide a rationale for combining PCB with checkpoint inhibition in lung cancer." @default.
• W2910094802 created "2019-01-25" @default.
• W2910094802 creator A5004228936 @default.
• W2910094802 creator A5012937808 @default.
• W2910094802 creator A5016567527 @default.
• W2910094802 creator A5016904876 @default.
• W2910094802 creator A5017960622 @default.
• W2910094802 creator A5020254778 @default.
• W2910094802 creator A5031007260 @default.
• W2910094802 creator A5051066209 @default.
• W2910094802 creator A5063631436 @default.
• W2910094802 creator A5080628121 @default.
• W2910094802 date "2019-04-01" @default.
• W2910094802 modified "2023-09-30" @default.
• W2910094802 title "Induction of Peripheral Effector CD8 T-cell Proliferation by Combination of Paclitaxel, Carboplatin, and Bevacizumab in Non–small Cell Lung Cancer Patients" @default.
• W2910094802 cites W1519460121 @default.
• W2910094802 cites W1757407923 @default.
• W2910094802 cites W1767508090 @default.
• W2910094802 cites W1983517349 @default.
• W2910094802 cites W2017364703 @default.
• W2910094802 cites W2037342985 @default.
• W2910094802 cites W2046094997 @default.
• W2910094802 cites W2056893124 @default.
• W2910094802 cites W2106539209 @default.
• W2910094802 cites W2145174070 @default.
• W2910094802 cites W2198093519 @default.
• W2910094802 cites W2210453860 @default.
• W2910094802 cites W2282550179 @default.
• W2910094802 cites W2301488980 @default.
• W2910094802 cites W2527905628 @default.
• W2910094802 cites W2528647848 @default.
• W2910094802 cites W2529904548 @default.
• W2910094802 cites W2576658154 @default.
• W2910094802 cites W2578528809 @default.
• W2910094802 cites W2594793697 @default.
• W2910094802 cites W2605630275 @default.
• W2910094802 cites W2609289346 @default.
• W2910094802 cites W2745683917 @default.
• W2910094802 cites W2753065806 @default.
• W2910094802 doi "https://doi.org/10.1158/1078-0432.ccr-18-2243" @default.
• W2910094802 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30642911" @default.
• W2910094802 hasPublicationYear "2019" @default.
• W2910094802 type Work @default.
• W2910094802 sameAs 2910094802 @default.
• W2910094802 citedByCount "28" @default.
• W2910094802 countsByYear W29100948022019 @default.
• W2910094802 countsByYear W29100948022020 @default.
• W2910094802 countsByYear W29100948022021 @default.
• W2910094802 countsByYear W29100948022022 @default.
• W2910094802 countsByYear W29100948022023 @default.
• W2910094802 crossrefType "journal-article" @default.
• W2910094802 hasAuthorship W2910094802A5004228936 @default.
• W2910094802 hasAuthorship W2910094802A5012937808 @default.
• W2910094802 hasAuthorship W2910094802A5016567527 @default.
• W2910094802 hasAuthorship W2910094802A5016904876 @default.
• W2910094802 hasAuthorship W2910094802A5017960622 @default.
• W2910094802 hasAuthorship W2910094802A5020254778 @default.
• W2910094802 hasAuthorship W2910094802A5031007260 @default.
• W2910094802 hasAuthorship W2910094802A5051066209 @default.
• W2910094802 hasAuthorship W2910094802A5063631436 @default.
• W2910094802 hasAuthorship W2910094802A5080628121 @default.
• W2910094802 hasConcept C121608353 @default.
• W2910094802 hasConcept C126322002 @default.
• W2910094802 hasConcept C154317977 @default.
• W2910094802 hasConcept C167672396 @default.
• W2910094802 hasConcept C202751555 @default.
• W2910094802 hasConcept C203014093 @default.
• W2910094802 hasConcept C2776090121 @default.
• W2910094802 hasConcept C2776256026 @default.
• W2910094802 hasConcept C2776694085 @default.
• W2910094802 hasConcept C2777292972 @default.
• W2910094802 hasConcept C2778239845 @default.
• W2910094802 hasConcept C2781451048 @default.
• W2910094802 hasConcept C502942594 @default.
• W2910094802 hasConcept C55493867 @default.
• W2910094802 hasConcept C71924100 @default.
• W2910094802 hasConcept C86803240 @default.
• W2910094802 hasConcept C8891405 @default.
• W2910094802 hasConceptScore W2910094802C121608353 @default.
• W2910094802 hasConceptScore W2910094802C126322002 @default.
• W2910094802 hasConceptScore W2910094802C154317977 @default.
• W2910094802 hasConceptScore W2910094802C167672396 @default.
• W2910094802 hasConceptScore W2910094802C202751555 @default.
• W2910094802 hasConceptScore W2910094802C203014093 @default.
• W2910094802 hasConceptScore W2910094802C2776090121 @default.
• W2910094802 hasConceptScore W2910094802C2776256026 @default.
• W2910094802 hasConceptScore W2910094802C2776694085 @default.
• W2910094802 hasConceptScore W2910094802C2777292972 @default.
• W2910094802 hasConceptScore W2910094802C2778239845 @default.
• W2910094802 hasConceptScore W2910094802C2781451048 @default.
• W2910094802 hasConceptScore W2910094802C502942594 @default.
• W2910094802 hasConceptScore W2910094802C55493867 @default.
• W2910094802 hasConceptScore W2910094802C71924100 @default.
• W2910094802 hasConceptScore W2910094802C86803240 @default.
• W2910094802 hasConceptScore W2910094802C8891405 @default.
• W2910094802 hasFunder F4320307779 @default.
• W2910094802 hasFunder F4320322777 @default.
• W2910094802 hasIssue "7" @default.

• next